Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,354.00
Bid: 12,354.00
Ask: 12,356.00
Change: 236.00 (1.95%)
Spread: 2.00 (0.016%)
Open: 12,244.00
High: 12,364.00
Low: 12,228.00
Prev. Close: 12,118.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

GLOBAL MARKETS-Stocks slide on surging virus cases, stimulus doubts; dollar rises

Mon, 26th Oct 2020 15:46

* Market recovery may take longer than hoped - OPEC
official

* Graphic: 2020 asset performance http://tmsnrt.rs/2yaDPgn
(Updates prices, changes comment, dateline; previous
LONDON/SYDNEY)

By Rodrigo Campos

NEW YORK, Oct 26 (Reuters) - Shares fell across the globe on
Monday as surging coronavirus cases in Europe and the United
States clouded the world economic outlook, giving the dollar a
safe-haven boost.

The United States, Russia and France set new daily records
for coronavirus infections as a resurgence of the virus swelled
across parts of the Northern Hemisphere, forcing some countries
to impose new curbs.

The spreading pandemic, along with no clear progress on a
U.S. stimulus package and caution ahead of the Nov. 3 U.S.
presidential election dragged the MSCI world equity index
down.

"The market is vulnerable to these 'bad headlines,' because
investors are generally so optimistic right now," said Willie
Delwiche, investment strategist at Baird in Milwaukee.

MSCI's gauge of stocks globally hit a record high in
September and brushed against it earlier this month.

"The market is set up for disappointment at this point,"
Delwiche said.

The Dow Jones Industrial Average fell 712.83 points,
or 2.52%, to 27,622.74, the S&P 500 lost 73.34 points, or
2.12%, to 3,392.05 and the Nasdaq Composite dropped
189.90 points, or 1.64%, to 11,358.38.

The pan-European STOXX 600 index lost 1.72% and
MSCI's gauge of stocks across the globe shed
1.69%.

Emerging market stocks lost 0.66%. MSCI's broadest index of
Asia-Pacific shares outside Japan closed 0.41%
lower, while Japan's Nikkei fell 0.09%.

Europe became the second region after Latin America to
surpass 250,000 deaths on Saturday, according to a Reuters
tally, as many European countries reported their highest number
of COVID-19 cases in a single day.

Sentiment was also hit by a survey showing German business
morale fell in October for the first time in six months.

Reports of progress in a COVID-19 vaccine being developed by
the University of Oxford and manufactured by drugmaker
AstraZeneca Plc helped limit some of the market
sell-off, analysts said.

As markets increasingly price in the likelihood of a
Democratic president and Congress which would likely result in a
rise in government spending and borrowing, U.S. 10-year Treasury
yields hit their highest since early June last week at 0.872%
.

"We have raised the probability of a Democratic sweep,
already our base case, from 40% to just over 50% and have
increased our expectation of (Democratic presidential
candidate)Biden to win from 65% to 75%," NatWest Markets
analysts said. "We see steeper U.S. yield curves and a weaker
USD as likely to prevail in our base case."

Benchmark 10-year notes last rose 13/32 in price
to yield 0.7977%, from 0.841% late on Friday.

BlackRock Inc, the world's largest asset manager, on
Monday downgraded U.S. Treasuries and upgraded their
inflation-linked peers ahead of the U.S. election.

Despite encouraging news about a COVID-19 vaccine out of
Oxford, surging coronavirus cases sent investors to the safety
of the dollar.

"Skittish investors are scooping up the greenback as virus
cases accelerate around the world, stimulus talks in Washington
remain in limbo, and trepidation is on the rise ahead of
America's presidential election," said Joe Manimbo, senior
market analyst, at Western Union Business Solutions in
Washington.

The dollar index rose 0.316%, with the euro
down 0.43% to $1.1808.

The Japanese yen weakened 0.15% versus the greenback at
104.90 per dollar, while sterling was last trading at
$1.3007, down 0.25% on the day.

In commodity markets, spot gold added 0.2% to
$1,904.46 an ounce. Silver fell 1.02% to $24.33.

Oil prices extended last week's losses. OPEC's secretary
general said an oil market recovery may take longer than hoped
as coronavirus inflections rise around the world, and OPEC and
its allies would "stay the course" in balancing the market.

U.S. crude was down 3.64% at $38.40 per barrel and
Brent was at $40.37, down 3.35% on the day.

(Reporting by Rodrigo Campos; additional reporting by Lewis
Krauskopf and Gertrude Chavez-Dreyfuss in New York, Ross Gerber
in Boston, Tom Arnold in London and Wayne Cole in Sydney;
Editing by Susan Fenton)

More News
16 Jan 2024 17:17

FTSE 100 hits one-month low, precious miners biggest drag

FTSE 100 down 0.5%, FTSE 250 flat

*

Read more
16 Jan 2024 16:17

London close: Stocks finish lower as wage growth eases

(Sharecast News) - London's stock markets finished in the red on Tuesday, as investors assessed the latest UK jobs data.

Read more
16 Jan 2024 11:58

LONDON MARKET MIDDAY: FTSE 100 falls despite cooler UK wage growth

(Alliance News) - The FTSE 100 in London was down at midday Tuesday, as investors nervously eye Wednesday's UK inflation data and what it will mean for interest rates.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
9 Jan 2024 10:50

Novartis in advanced talks to buy Cytokinetics- source

Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.

Read more
8 Jan 2024 14:08

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
6 Jan 2024 17:44

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
5 Jan 2024 12:00

Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference

NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.

Read more
3 Jan 2024 17:48

London close: Stocks fall amid rising geopolitical concerns

(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.

Read more
3 Jan 2024 16:52

LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes

(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.

Read more
3 Jan 2024 11:07

Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'

(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.

Read more
3 Jan 2024 10:16

IN BRIEF: Nuformix narrows annual loss as develops drug assets

Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.

Read more
3 Jan 2024 10:12

AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

Read more
3 Jan 2024 09:23

LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.